<DOC>
	<DOCNO>NCT00190580</DOCNO>
	<brief_summary>The purpose study prove hypothesis progression renal cardiovascular disease efficiently prevent angiotensin II receptor blocker valsartan add conventional antihypertensive therapy .</brief_summary>
	<brief_title>Kanagawa Valsartan Trial ( KVT ) : Effects Valsartan Renal Cardiovascular Disease</brief_title>
	<detailed_description>It widely recognize suppression renin-angiotensin system ameliorate progression chronic kidney disease ( CKD ) CKD important risk factor development cardiovascular disease . However , fully clarify amelioration CKD lead low incidence cardiovascular disease . The purpose study determine whether angiotensin II receptor antagonist valsartan , combination conventional antihypertensive therapy , ameliorate progression CKD cardiovascular disease . The primary outcome course renal cardiac function . The secondary outcome composite double serum creatinine concentration , end-stage renal disease , myocardial infarction , coronary revascularization , stroke , hospitalization unstable angina , hospitalization heart failure death cardiovascular cause .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>CKD serum creatinine 2.0 mg/dl Blood pressure 130/85 mmHg 20 year old Endstage renal disease maintenance dialysis Polycystic kidney disease Collagen disease Malignant accelerate hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>CKD</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>hypertension</keyword>
	<keyword>angiotensin II receptor blocker</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>valsartan</keyword>
	<keyword>KVT</keyword>
</DOC>